CEACAM6 and COVID-19: CEACAM6 has been identified as having high expression in Type II pneumocytes in COVID-19 patients, the cells targeted by SARS-CoV-250, and it has been suggested that cross-talk between Type II pneumocytes and developing neutrophils in COVID-19 occurs via CEACAM8-CEACAM649.